Guangdong Biolight Meditech Co Ltd
Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, el… Read more
Guangdong Biolight Meditech Co Ltd (300246) - Net Assets
Latest net assets as of September 2025: CN¥1.29 Billion CNY
Based on the latest financial reports, Guangdong Biolight Meditech Co Ltd (300246) has net assets worth CN¥1.29 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.53 Billion) and total liabilities (CN¥1.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.29 Billion |
| % of Total Assets | 50.91% |
| Annual Growth Rate | 23.08% |
| 5-Year Change | 25.01% |
| 10-Year Change | 180.15% |
| Growth Volatility | 71.08 |
Guangdong Biolight Meditech Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Guangdong Biolight Meditech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangdong Biolight Meditech Co Ltd (2008–2024)
The table below shows the annual net assets of Guangdong Biolight Meditech Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.29 Billion | -7.04% |
| 2023-12-31 | CN¥1.39 Billion | -7.55% |
| 2022-12-31 | CN¥1.50 Billion | +51.40% |
| 2021-12-31 | CN¥992.38 Million | -3.92% |
| 2020-12-31 | CN¥1.03 Billion | +76.30% |
| 2019-12-31 | CN¥585.84 Million | -5.84% |
| 2018-12-31 | CN¥622.19 Million | +12.29% |
| 2017-12-31 | CN¥554.08 Million | +9.88% |
| 2016-12-31 | CN¥504.27 Million | +9.42% |
| 2015-12-31 | CN¥460.87 Million | +7.69% |
| 2014-12-31 | CN¥427.94 Million | +8.65% |
| 2013-12-31 | CN¥393.88 Million | +4.22% |
| 2012-12-31 | CN¥377.93 Million | +6.67% |
| 2011-12-31 | CN¥354.32 Million | +293.99% |
| 2010-12-31 | CN¥89.93 Million | +34.35% |
| 2009-12-31 | CN¥66.94 Million | +43.85% |
| 2008-12-31 | CN¥46.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Biolight Meditech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3048.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥435.27 Million | 35.72% |
| Common Stock | CN¥264.58 Million | 21.71% |
| Other Comprehensive Income | CN¥131.32 Million | 10.78% |
| Other Components | CN¥387.51 Million | 31.80% |
| Total Equity | CN¥1.22 Billion | 100.00% |
Guangdong Biolight Meditech Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Biolight Meditech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
$361.00 Million |
|
Hyster-Yale Materials Handling Inc
NYSE:HY
|
$361.11 Million |
|
enCore Energy Corp.
V:EU
|
$361.16 Million |
|
Shenzhen Etmade Automatic Equipment
SHE:300812
|
$361.30 Million |
|
Venturex Resources Ltd (Australia)
PINK:VTEXF
|
$360.74 Million |
|
IRPC PCL -NVDR- BA 1
F:NVPF
|
$360.73 Million |
|
Finnair Oyj
PINK:FNNNF
|
$360.48 Million |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
$360.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Biolight Meditech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,310,894,066 to 1,218,676,708, a change of -92,217,358 (-7.0%).
- Net loss of 71,441,315 reduced equity.
- Dividend payments of 17,622,448 reduced retained earnings.
- Share repurchases of 20,010,000 reduced equity.
- Other comprehensive income increased equity by 131,316,062.
- Other factors decreased equity by 114,459,657.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-71.44 Million | -5.86% |
| Dividends Paid | CN¥17.62 Million | -1.45% |
| Share Repurchases | CN¥20.01 Million | -1.64% |
| Other Comprehensive Income | CN¥131.32 Million | +10.78% |
| Other Changes | CN¥-114.46 Million | -9.39% |
| Total Change | CN¥- | -7.03% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Biolight Meditech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 50.72x to 3.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.29 | CN¥14.48 | x |
| 2009-12-31 | CN¥0.41 | CN¥14.48 | x |
| 2010-12-31 | CN¥0.56 | CN¥14.48 | x |
| 2011-12-31 | CN¥2.45 | CN¥14.48 | x |
| 2012-12-31 | CN¥1.69 | CN¥14.48 | x |
| 2013-12-31 | CN¥1.77 | CN¥14.48 | x |
| 2014-12-31 | CN¥1.87 | CN¥14.48 | x |
| 2015-12-31 | CN¥1.91 | CN¥14.48 | x |
| 2016-12-31 | CN¥2.12 | CN¥14.48 | x |
| 2017-12-31 | CN¥2.31 | CN¥14.48 | x |
| 2018-12-31 | CN¥2.57 | CN¥14.48 | x |
| 2019-12-31 | CN¥2.50 | CN¥14.48 | x |
| 2020-12-31 | CN¥4.18 | CN¥14.48 | x |
| 2021-12-31 | CN¥4.08 | CN¥14.48 | x |
| 2022-12-31 | CN¥5.46 | CN¥14.48 | x |
| 2023-12-31 | CN¥4.97 | CN¥14.48 | x |
| 2024-12-31 | CN¥4.64 | CN¥14.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Biolight Meditech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.74%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.05x
- Recent ROE (-5.86%) is below the historical average (12.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 22.70% | 12.24% | 1.10x | 1.68x | CN¥5.91 Million |
| 2009 | 30.48% | 19.73% | 1.00x | 1.54x | CN¥13.71 Million |
| 2010 | 36.68% | 22.97% | 1.12x | 1.42x | CN¥24.00 Million |
| 2011 | 9.53% | 21.36% | 0.40x | 1.12x | CN¥-1.66 Million |
| 2012 | 9.85% | 20.03% | 0.42x | 1.17x | CN¥-547.29K |
| 2013 | 7.52% | 12.32% | 0.50x | 1.23x | CN¥-9.56 Million |
| 2014 | 8.22% | 11.70% | 0.56x | 1.26x | CN¥-7.33 Million |
| 2015 | 5.58% | 6.29% | 0.66x | 1.35x | CN¥-18.95 Million |
| 2016 | 14.46% | 11.30% | 0.87x | 1.48x | CN¥20.70 Million |
| 2017 | 11.38% | 8.09% | 0.89x | 1.58x | CN¥6.99 Million |
| 2018 | 11.42% | 7.89% | 0.89x | 1.63x | CN¥7.98 Million |
| 2019 | 11.82% | 7.83% | 0.86x | 1.76x | CN¥9.96 Million |
| 2020 | 37.71% | 24.80% | 0.87x | 1.75x | CN¥254.35 Million |
| 2021 | 7.14% | 5.85% | 0.63x | 1.92x | CN¥-25.60 Million |
| 2022 | 1.56% | 1.87% | 0.49x | 1.72x | CN¥-119.50 Million |
| 2023 | -4.97% | -5.46% | 0.47x | 1.93x | CN¥-196.27 Million |
| 2024 | -5.86% | -6.74% | 0.42x | 2.05x | CN¥-193.31 Million |
Industry Comparison
This section compares Guangdong Biolight Meditech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,032,562,305
- Average return on equity (ROE) among peers: 25.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Biolight Meditech Co Ltd (300246) | CN¥1.29 Billion | 22.70% | 0.96x | $360.97 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |